Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 358-368

  Preisler, Harvey D ^a   Raza, A ^a   Bonomi, P ^a   Taylor, S ^a   LaFolette, S ^a   Leslie, W ^a   Lincoln, S ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; BROXURIDINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IDOXURIDINE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HUMAN; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TESTIS TUMOR; TREATMENT FAILURE; TUMOR GROWTH;

EID: 0030795179     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039740     Document Type: Review

References (64)

1. Raza A, Preisler HD, Day R, et al: Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A Leukemia Intergroup study. Blood 76(11):2191-2197, 1990.
2. Christensson B, Tribukaint B, Linden IL, et al: Cell proliferation and DNA content in non-Hodgkin's lymphoma. Cancer 58:1295-1304, 1986.
3. Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 40:1890-1896, 1980.
4. Silverstrini R, Daidone MG, Valagressa P, et al: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:375-379, 1987.
5. Clark GM, Dressier LG, Owens MA, et al: Prediction of relapse and survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989.
6. Hoshino T, Nagashima T, Murovic JA, et al: Cell kinetic analysis of human malignant brain tumor (gliomas). Cancer 44:956-962, 1979.
7. Hoshino T, Nagashima T, Murovic JA, et al: Proliferative potential of human meningiomas of the brain. A cell kinetic study with bromodeoxyuridine. Cancer 56:1466-1472, 1986.
8. Tubiana M: Repopulation in human tumors. Acta Oncol 27(Fasc 2):83-88, 1988.
9. Raza A, Maheswhari Y, Brereton W, et al: An analysis of the cell cycle characteristics and course of the disease in ANLL. Am J Hematol 24:65-75, 1987.
10. Preisler HD, Raza A, Larson R: Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk Res 15:773-780, 1991.
11. Preisler HD, Larson RA, Raza A, et al: The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: Response to treatment and treatment failure. Br J Haematol 79:390-397, 1991.
12. Masterson M, Raza A, Yousuf N, et al: Cell cycle kinetics in newly diagnosed childhood acute lymphoblastic leukemia. Proc Am Soc Hematol Blood 78(10): 1991 (abstract #151).
13. Tura S: A clinical trial of early splenectomy, hydroxyurea and cycling cytosine arabinoside, vincristine, and prednisonein chronic myeloid leukemia. Italian Cooperative Study Group in Chronic Myeloid Leukemia. Ser Hematol 8:121-125, 1975.
14. Cunningham I, Gee T, Dowling M: Results of treatment of Ph′ + chronic myelogenous leukemia with an intensive treatment regimen (L 5 Protocol). Blood 53:375-385, 1979.
15. Carella AM, Podesta M, Frassoni F: Collection of "normal" blood repopulation cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12(3):267-271, 1993.
16. Preisler HD, Raza A, Bacharani M: Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. Leuk Lymph 11(Suppl 1):303-306, 1993.
17. Preisler HD, Raza A, Higby D, et al: Treatment of myeloid blastic crisis of chronic myelogenous leukemia. Cancer Treat Rep 68(11):1351-1355, 1984.
18. Lambertenghi-Deiliers G, Annaloro C, Cortellaro M, et al: Idarubicin in blastic crisis of chronic myelogenous leukemia. Haematologica 76(5):406-408, 1991.
19. Bentzen SM, Johansen LV, Overgard J, et al: Clinical radiology of squamous cell carcinoma of the oropharynx. Int J Radiol Oncol Biol Phys 20:1197-1206, 1991.
20. Bentzen SM, Thames HD: Clinical evidence for tumor colonogen regeneration: Interpretations of data. Radiother Oncol 22:161-166, 1991.
21. Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27(Fasc2):131-146, 1988.
22. Fowler JF: Rapid repopulation in radiotherapy: A debate on mechanism. Radiother Oncol 22:156-158, 1991.
23. Fowler JF: How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother Oncol 18:165-181, 1990.
24. Begg C, Hofland I, Van Gloabekke M, et al: Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: Result from the EORTC Cooperative Trial 22851. Semin Radiat Oncol 2:22-26, 1992.
25. Merlano M, Como R, Margarino G, et al: Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. Cancer 67:915-921, 1991.
26. Preisler HD, Kotelnkov V, LaFollette S, et al: Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy. Clin Cancer Res 2:1453-1460, 1996.
27. Preisler HD, Gopal V: Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 18:149-160, 1994.
28. Johnson GJ, Costello WG, Oken MM, et al: Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). Cancer 52:1133-1141, 1983.
29. Carde P, Meerwaldt JH, Van Glabbeke MV, et al: Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkins lymphoma. Ann Oncol 2:431-435, 1991.
30. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkins lymphoma. N Engl J Med 327:1336-1341, 1992.
31. Louie AC, Gallagher JG, Sikora K, et al: Follow-up observations on the effects of human leukocyte interferon in non-Hodgkin's lymphoma. Blood 58:712-718, 1981.
32. Foon KA, Sherwin S A, Abrams PG, et al: Treatment of advanced non-Hodgkins lymphoma with recombinant/leukocyte a-interferon. N Engl J Med 311:1148-1152, 1984.
33. Horning SJ, Merigan TC, Krown SE, et al: Human interferon alpha in malignant lymphoma and Hodgkin's disease. Cancer 56:1305-1310, 1985.
34. Baron S, Tyring AK, Fleischman R, et al: The interferons: Mechanisms of action and clinical applications. JAMA 266:1375-1383, 1991.
35. Preisler HD, Gopal V, Banavali SD, et al: Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res 52:1-7, 1992.
36. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med 328:1002-1006, 1993.
37. Norin T, Onyango J: Radiotherapy in Burkitt's lymphoma: Conventional or superfractionated regime - Early results. Int I Radiat Oncol Biol Phys 2:399-406, 1977.
38. Yunis JJ, Mayer MD, Arnesen MA, et al: bcl-2 and othergenomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320:1047-1049, 1989.
39. Vaux DL, Cory S, Adams JM: bcl-2 gene promotes hemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
40. Miyashita T, Reed JC: bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993.
41. Campus L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096, 1993.
42. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598-606, 1993.
43. Birch R, Loehrer P, Williams S, et al: The effects of delay of therapy on response to cisplatin chemotherapy in disseminated germ cell tumors. Proc Am Soc Clin Oncol 5:105, 1986 (abstract #409).
44. Mellstedt H, Osterborg A, Bjorkholm M: Treatment of multiple myeloma with Interferon alpha: The Scandinavian experience. Br J Haematol 79(Suppl 1):21-25, 1991.
45. Oken MM, Kyle RA, Greipp PR, Connell MJ, et al: Possible survival benefit with chemotherapy plus Interferon in the treatment for multiple myeloma. Proc Am Soc Clin Oncol 11:A1234, 1992.
46. Osterborg A, Bjorkholm M, Bjoreman M, et al: Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III; a randomized study from the Myeloma Group of Central Sweden. Blood 81:1428-1434, 1993.
47. Corrado C, Pavlovsky S, Saslasky J, et al: Randomized trial comparing melphalan-prednisone with or without recombinant alpha 2 interferon in multiple myeloma. Proc Am Soc Clin Oncol 8: 1989 (abstract #1007).
48. Cooper MR, Dean K, McIntyre OR: A randomized study comparing melphalan/prednisone with or without alpha 2B-interferon in newly diagnosed multiple myeloma. Blood Proc Am Soc Hematol 76(10)(Suppl 1): 1990 (abstract #1371).
49. Mandelli F, Arvisati G, Amadori S: Maintenance treatment with recombinant Interferon alfa-2B in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430-1434, 1990.
50. Perez A, Stanley K, Rubin P, et al: A prospective study of various radiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer 45:2744-2753, 1980.
51. Torres J, Lee D, Leibel S, et al: Local control and reduced complications in split course irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 7:43-47, 1980.
52. Preisler HD, Raza A, Larson R: Alteration of the proliferative rate of acute myelogenous leukemia cells in-vivo in patients. Blood 80(10):2600-2603, 1992.
53. Preisler HD, Kotelnikov V, Hegde U: A strategy for overcoming regrowth resistance in chronic myelogenous leukemia. Am Soc Hematol meeting December 1994 (submitted).
54. Raza A, Gezer S, Mundle S, et al: Apoptosis in bone marrow biopsies involving stromal and hematopoietic cells in 45 patients with myelodysplastic syndromes. Blood, 1994 (submitted).
55. Mattson K, Nitranen A, Hodsti L, et al: Low dose α-interferon as maintenance therapy for small cell lung cancer. Proc Am Soc Clin Oncol 8: 1989 (abstract #883).
56. Lotan R, Hong WK, Kim JS, et al: Modulation of the expression of squamous differentiation markers in cultured human head and neck squamous carcinoma cells by retinoic acid. Proc Am Assoc Cancer Res 29:A161, 1988.
57. Sacchi M, Kaplan I, Johnson JT, et al: Antiproliferative effects of cytokines on squamous cell carcinoma. Acta Otolaryngol Head Neck Surg 117:321-126, 1991.
58. Meyskins FL, Gilmartin E, Alberts D, et al: Activity of isotretinoion against squamous cell cancer and pre-neoptastic lesions. Cancer Treat Rep 66:1315-1319, 1982.
59. Agawala S, Vlock D, Johnson J, et al: Phase II trial of interferon alpha in locally recurrent metastatic head and neck cancer: Results of ECOG trial P-2386. Proc Am Soc Clin Oncol 10:A684, 1991.
60. Preisler HD: Clinical studies in progress at the Rush Cancer Institute.
61. Banavali S, Pancoast J, Tricot G, et al: Serial studies of C-MYC expression in bone marrow biopsies: Effects of cytotoxic agents, rhGM-CSF and retinoic acid-interferon. Eur J Cancer 29A(8): 1162-1167, 1993.
62. Vlock DR, Johnson J, Myers E, et al: Preliminary trial of non-combinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 13:15-21, 1991.
63. Eisenhanen EA, Lippman SM, Kavanagh JJ: Combination 13-cisretinic acid and interferon α-2a in the therapy of solid tumors. Leukemia 8:1622-1625, 1994.
64. Weidmann E, Sacchi M, Plaisance S, et al: Receptors for IL2 in human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 52:5963-5970, 1992.